The stock of Exelixis Inc (EXEL) has gone up by 3.53% for the week, with a 24.87% rise in the past month and a 37.87% rise in the past quarter. The volatility ratio for the week is 2.10%, and the volatility levels for the past 30 days are 2.63% for EXEL. The simple moving average for the last 20 days is 2.00% for EXEL stock, with a simple moving average of 43.70% for the last 200 days.
Is It Worth Investing in Exelixis Inc (NASDAQ: EXEL) Right Now?
Exelixis Inc (NASDAQ: EXEL) has a price-to-earnings ratio that is above its average at 22.86x. The stock has a 36-month beta value of 0.52. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 5 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EXEL is 278.44M, and at present, short sellers hold a 2.84% of that float. On November 27, 2024, the average trading volume of EXEL was 2.07M shares.
EXEL) stock’s latest price update
Exelixis Inc (NASDAQ: EXEL) has seen a decline in its stock price by -1.58 in relation to its previous close of 36.45. However, the company has experienced a 3.53% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-27 that The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with RBC Capital Mkts repeating the rating for EXEL by listing it as a “Outperform.” The predicted price for EXEL in the upcoming period, according to RBC Capital Mkts is $34 based on the research report published on October 16, 2024 of the current year 2024.
UBS, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $30. The rating they have provided for EXEL stocks is “Neutral” according to the report published on September 19th, 2024.
Barclays gave a rating of “Equal Weight” to EXEL, setting the target price at $25 in the report published on April 11th of the current year.
EXEL Trading at 17.87% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.30% of loss for the given period.
Volatility was left at 2.63%, however, over the last 30 days, the volatility rate increased by 2.10%, as shares surge +10.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.37% upper at present.
During the last 5 trading sessions, EXEL rose by +3.23%, which changed the moving average for the period of 200-days by +76.82% in comparison to the 20-day moving average, which settled at $35.16. In addition, Exelixis Inc saw 49.54% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXEL starting from Haley Patrick J., who sale 10,000 shares at the price of $35.27 back on Nov 22 ’24. After this action, Haley Patrick J. now owns 278,665 shares of Exelixis Inc, valued at $352,700 using the latest closing price.
PATRICK JOSEPH HALEY, the Officer of Exelixis Inc, proposed sale 10,000 shares at $35.27 during a trade that took place back on Nov 22 ’24, which means that PATRICK JOSEPH HALEY is holding shares at $352,700 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- 0.25 for the present operating margin
- 0.96 for the gross margin
The net margin for Exelixis Inc stands at 0.22. The total capital return value is set at 0.2. Equity return is now at value 20.20, with 15.73 for asset returns.
Currently, EBITDA for the company is 196.6 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 4.89. The receivables turnover for the company is 7.72for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.93.
Conclusion
To sum up, Exelixis Inc (EXEL) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
